|

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

RECRUITINGPhase 4Sponsored by Samsung Medical Center
Actively Recruiting
PhasePhase 4
SponsorSamsung Medical Center
Started2024-02-01
Est. completion2027-08-01
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07776054

Summary

SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥19 years
* Persistent atrial fibrillation
* H2FPEF score ≥6 or HFA-PEFF score ≥5
* Restoration of sinus rhythm after electrical cardioversion

Exclusion Criteria:

* Previous use of an SGLT2 inhibitor
* Intracardiac thrombus on transesophageal echocardiography
* Refusal to participate

Conditions4

Atrial FibrillationDC CardioversionHeart DiseaseSGLT2 Inhibitor

Interventions1

SGLT2 inhibitors (Dapagliflozin and Empagliflozin)

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.